Treatments for diseases accelerated by metabolic waste-products such as gouty arthritis, and chronic kidney disease.
Reduction of unwanted metabolic waste-products
Rebalanced microbiome
Safe & tolerable
Oral administration
Clinical trials
Beo Therapeutics has initiated two phase 1/2 clinical trials in more than 100 patients with hyperuricemia to study the safety, mode of action and efficacy of BEO 001.